Coya Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Coya Therapeutics, a clinical-stage biotech, reported a $21.2 million net loss for 2025 while advancing its lead asset COYA 302 into Phase 2 for ALS and receiving IND acceptance for FTD, supported by a recent $11.1 million financing.
NASDAQ
10-K/A: Coya Therapeutics Files Amendment No. 1 to Form 10-K/A for Fiscal Year Ended December 31, 2024
Coya Therapeutics files an amendment to its annual report on Form 10-K/A to include previously omitted Part III information and updated certifications.
NASDAQ
Coya Therapeutics, a clinical-stage biotechnology company, announces its 10-K filing, highlighting pipeline expansion and financial results for the year ended December 31, 2024.
NASDAQ
Coya Therapeutics has partnered with Dr. Reddy's for the development and commercialization of COYA 302 in key markets, while also securing significant funding through a private placement.